PER® New York GU | Conference

Frontline mRCC Paradigm Crowds Among Immune-Based Treatment Options

March 13th 2021

The emergence of multiple combination regimens with immunotherapy and TKIs has been welcome for the frontline treatment of patients with metastatic renal cell carcinoma; however, without head-to-head comparative data, treatment selection has become individualized based on available patient characteristics.

Novel Targeted and Immunotherapeutic Agents Reshape Metastatic Urothelial Cancer Landscape

March 12th 2021

Treatment options for patients with metastatic urothelial cancer have rapidly expanded as FDA approvals of immunotherapeutics push the boundaries of a once stagnant treatment landscape. Combination regimens and the addition of targeted approaches, further demonstrate progress in areas that have been tough to crack.

Novel Hormonal Agents Foster New Approaches in Nonmetastatic CRPC

April 1st 2020

Nonmetastatic castration-resistant prostate cancer is a more recently defined clinical state of prostate cancer, for which several approved drugs are now available.

PD-1 Inhibition Reigns Supreme in Frontline Advanced RCC

March 31st 2020

The role of immunotherapy in metastatic renal cell carcinoma has grown tremendously with dual immune checkpoint inhibition and combinations of anti–PD-1/VEGF inhibitors.

PARP Investigations Continue on Path Toward Precision Medicine in Prostate Cancer

March 31st 2020

The use of PARP inhibitors against DNA damage repair alterations in prostate cancer is the first display of the potential for widespread precision medicine in the field.

Immunotherapy Combinations Are King in Frontline RCC Treatment

March 14th 2020

In metastatic renal cell carcinoma, the use of frontline combination immunotherapy regimens has led to significant survival benefits for patients, and efforts are now being focused on exploring novel options for those who become refractory to this approach.

Dr. Gomella on the State of Genetic Testing and Screening in Prostate Cancer

March 14th 2020

Leonard G. Gomella, MD, professor, chair, Department of Urology, and director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the state of genetic testing in prostate cancer.

Gomella Offers Guidance on Screening, Genetic Testing in Prostate Cancer

March 14th 2020

Leonard G. Gomella, MD, discusses the state of genetic testing in prostate cancer, shares his recommendations for screening, and provides perspective on where the field is headed.

Dr. Petrylak on Available Treatment Options in Metastatic Bladder Cancer

March 13th 2020

Daniel P. Petrylak, MD, discusses available treatment options in metastatic bladder cancer.

Further Study Is Needed to Maximize Therapeutic Benefit in Urothelial Cancer

March 13th 2020

In metastatic urothelial cancer, the portfolio of immunologic therapies is robust, but the treatment paradigm for these agents requires refinement.

Dr. Pal on Biomarker Development in Renal Cell Carcinoma

July 15th 2016

Sumanta Kumar Pal, MD, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses biomarker development in the field of renal cell carcinoma (RCC).

Dr. Crawford on Ongoing Research With Radium-223 in mCRPC

July 15th 2016

E. David Crawford, MD, professor of Radiation Oncology, Department of Surgery, University of Colorado Denver, discusses ongoing research with radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Stock on the Optimal Use of Radium-223 in mCRPC

April 25th 2016

Richard G. Stock, MD, senior faculty, Radiation Oncology, Mount Sinai Hospital, discusses the optimal use of radium-223 dichloride (Xofigo) for the treatment of patients with metastatic castration-resistant prostate cancer.

Dr. Choueiri on Using Immunotherapy to Treat RCC

April 11th 2016

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses why community oncologists should utilize immunotherapy agents to treat patients with renal cell carcinoma.

Dr. Gomella on Current Perspectives on Prostate Cancer Screening

April 1st 2016

Leonard Gomella, MD, physician, professor, and chair of the Department of Urology at Thomas Jefferson University and director of the Kimmel Cancer Center Network, discusses the current perspectives on screening for prostate cancer.

Novel Bladder Cancer Strategies Target PD-1/PD-L1 and VEGF Pathways

March 29th 2016

Emerging agents targeting the PD1/PD-L1 pathway and the process of angiogenesis are shaping up to be promising options to break a 30-year drought in new therapies for patients with progressive metastatic urothelial bladder cancer.

Dr. Petrylak on Immunotherapy in Bladder Cancer

March 28th 2016

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses immunotherapy agents for the treatment of patients with bladder cancer.

Gomella Discusses Radium-223 Impact in mCRPC

March 23rd 2016

Leonard Gomella, MD, discusses the optimal patient population to receive radium-223 for prostate cancer and how oncologists should best use it.

Questions Loom Over Androgen-Targeting Strategies in Metastatic Prostate Cancer

March 22nd 2016

Targeting androgen receptor signaling with recently approved agents has improved outcomes for men with metastatic castration-resistant prostate cancer but significant questions linger about how to tackle resistance to the therapies.

Dr. Dreicer on the Optimal Use of Radium-223 in Prostate Cancer

March 21st 2016

Robert Dreicer, MD, professor, Department of Medicine, Division of Hematology/Oncology, University of Virginia Health System, discusses the optimal use of radium-223 dichloride (Xofigo) for patients with metastatic castration-resistant prostate cancer.